Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021
Destiny Pharma PLC (Purpose:DEST) (Destiny Pharma PLC (Purpose:DEST)) is a clinical stage, modern biotechnology organization focused on the progress of novel medicines that can prevent lifestyle-threatening bacterial infections. The company’s pipeline has novel microbiome-based mostly biotherapeutics and XF drug clinical belongings together with NTCD-M3, a Stage three prepared treatment for the prevention of C. difficile an infection (CDI) recurrence which is the primary result in of healthcare facility acquired bacterial infections in the US. Destiny’s pipeline also includes XF-73 nasal gel, which has not long ago concluded a good Stage 2b clinical trial targeting the prevention of post-surgical staphylococcal healthcare facility bacterial infections together with MRSA. The organization is also co-building SPOR-COV, a novel, biotherapeutic merchandise for the prevention of COVID-19 and other viral respiratory bacterial infections.
